Introduction: Ticagrelor is used for the prevention of thrombotic events in patients with acute coronary syndrome or myocardial infarction with ST elevation. The drug is combined with acetylsalicylic acid (ASA - Aspirin) unless the latter is contraindicated. The FDA indication for ticagrelor is reduction of the rate of cardiovascular death, myocardial infarction (MI), and stroke in people with acute coronary syndrome or history of myocardial infarction. AHA/ACC Guidelines 2014 state: It is reasonable to choose ticagrelor over clopidogrel for P2Y12 inhibition treatment in patients with NSTE-ACS treated with early invasive strategy and/or coronary stenting [1]. The most common side effects are shortness of breath (dyspnea, 1%) and various types of bleeding, such as hematoma, gastrointestinal, subcutaneous, intracranial hemorrhage... In addition to this, knowing the contraindications of Ticagrelor to prevent hemorrhagic complications. Case presentation: A 60-year-old man was admitted to. He had been receiving loading dose 180mg ticagrelor and 250mg aspirin and Heparin for a recent acute coronary syndrome (ACS) that had been treated with one bare-metal stent and developed a major esophageal bleeding, pericardial effusion. 48 hours later, the patient had a decreased level of consciousness. Computed tomography (CT) revealed an intracranial hemorrhage peri-rolandic. Patient presented a cardiogenic shock (cardiac pump failure related to loss of myocardial contractility) with EF: 15% (under dobutamine) and Hypovolemic shock (due to blood loss) combined. He proceeded to emergency cardiac transplantation operation. Apart from dual antiplatelet therapy (DAPT) with aspirin and ticagrelor, there were no other identified risk factors for increased bleeding. Conclusion: In cardiac surgical, patients who are treated with ticagrelor & ASA until and after surgery, ticagrelor therapy is associated with a significantly higher blood loss, a significantly higher use of blood products and coagulation factors and higher incidence of rethoracotomies for bleeding. Consequently, Ticagrelor intake for ACS patients should be avoided or at least discontinued 3 days before cardiac surgery.

Keywords: Cardiac surgery, Ticagrelor, Hemorrhage, Coronary Artery Disease, ACS, Cardiogenic Shock, Hypovolemic shock

List of abbreviations

ACS(Acute coronary syndrome) , CT (Computed tomodraphy), ECG (Electrocardiograma), CAG (corony angiography), CK (creatin kinase), ASA ( Acetylsalicylic Acid) , STEmI (ST elevation myocardial infarction), NSTEMI (non ST elevation myocardial infarction) , CAD (coronary artery disease), TV ( Tachycardia ventricular), DAPT (Dual Antiplatelet therapy), MI (myocardial infarction), CABG (Coronary artery bypass grafting)

1. Introduction

Ticagrelor is an orally active P2Y12 receptor blocker that does not require metabolic conversion to an active form. Ticagrelor binds directly to the P2Y12 receptor and can more completely inhibit the sustained platelet aggregation response to ADP than clopidogrel. The use of ticagrelor for reducing thrombotic cardiovascular events in patients with acute coronary syndromes is more suggested.

Ticagrelor is absorbed quickly from the gut, the bioavailability being 36%, and reaches its peak concentration after about 1.5 hours. The main metabolite, AR-C124910XX, is formed quickly via CYP3A4 by dehydroxyethylation at position 5 of the cyclopentane ring. It peaks after about 2.5 hours. Both ticagrelor and AR-C124910XX are bound to plasma proteins (>99.7%), and both are pharmacologically active. Blood plasma concentrations are linearly dependent on the dose up to 1260 mg (the sevenfold daily dose). The metabolite reaches 30–40% of ticagrelor's plasma concentrations. Drug and metabolite are mainly excreted via bile and feces.

Based on data from PLATO and TRITON-TIMI 38, the newer platelet inhibitors ticagrelor have been incorporated in the current European Society of Cardiology (ESC) guidelines[2]. Whilst their efficacy is undeniable, bleeding is an issue albeit at comparable rates with clopidogrel. We describe a case of internal bleeding, itself a rare entity, in a patient on ticagrelor post primary PCI for an leftmain STEMI, to underscore the risk of life threatening bleeding with the use of these new agents [3]

2. Case Report

A 59 years-old man, without the ACS risk factors, was admitted in Cardiologic Intensive Care Unit for an anterior ST-ACS in cardiogenic shock. A percutaneous coronary (PCI) was performed after a loading dose of unfractionated heparin (5000 UI), and found an occlusion of the left main coronary artery. Thrombo-ectomy and active stenting were performed while he received a loading dose of 250mg of aspirin and 180mg of ticagrelor. Secondary followed by a maintenance dose of respectively 75mg per day and 90mg twice a day.

Post-operative stay was complicated by a digestive hemorrhage and a major cardiac failure. Digestive endoscopy found a bleeding gastric ulcer, treated by local adrenalin injection and general daily injection of...
esomeprazole. Concerning the cardiac failure, after a discussion with the heart team he was decided to register the patient on the national heart transplant inpatient. In bridge to transplant, and Extracorporeal Life Support (ECLS) was implanted. HE underwent cardiac transplant 8 days later while on dual antiplatelet therapy (DAPT), using extracorporeal circulation with heparin (16 000 UI), reversed by protamine (150 UI). Peri-operative blood loss was important because global hemorrhage without effect of protamine, cells transfusion (red cells, platelets), fibrinogen and plasma. Re-intervention happened a few hours later due to ongoing life threatening hemorrhage and disseminated intravascular coagulation (DIC): at opening, we found a mediastinal hematoma, a bilateral hememothorax around 2 liters and a cardiac tamponade. All cardiac stiches were blood free. Unfortunately, despite redo-surgery and polytransfusion, bleeding remains important and patient died on post-operative day one with a hemorrhagic shock and multi visceral organ failure. In total during the peri-operative course, he received 44 red cells units, 7 units of autologous transfusion, bleeding remains important and patient died on post-operative day one with a hemorrhagic shock and disseminated intravascular coagulation (DIC): at opening, we found a mediastinal hematoma, a bilateral hememothorax around 2 liters and a cardiac tamponade. All cardiac stiches were blood free. Unfortunately, despite redo-surgery and polytransfusion, bleeding remains important and patient died on post-operative day one with a hemorrhagic shock and multi visceral organ failure. In total during the peri-operative course, he received 44 red cells units, 7 units of autologous platelet, 21 units of fresh frozen plasma, 12mg of prococonvertine, and 10.5mg of fibrinogen.

3. Discussion

DAPT with aspirin and ticagrelor, there were no other identified bleeding in this patient?

A study 100 patients with Ticagrelor following PCI for STEACS (n = 45) or NSTEACS (n = 55): At 30 days there was no death, fatal and minor bleeding (TIMI criteria). There were 19 (19%) incidences of bleeding within the first 30 days. The majority of bleeding (13/19, 68%) was minimal bleeding from the access site. One patient (1%) experienced major bleeding (colonic polyp) with a haemoglobin fall above 5 g/L. Five patients experienced bleeding requiring medical attention. Two of these patients had gastrointestinal bleeding (gastric ulcer, colon cancer), the rest presented with a haemoglobin drop without apparent primary source [4].

A nationwide study, all acute coronary syndrome patients in Sweden on dual antiplatelet therapy with aspirin and ticagrelor (n = 1266) or clopidogrel (n = 978) who underwent CABG during 2012–13 were included in a retrospective observational study. The incidence of major bleeding complications according to the Bleeding Academic Research Consortium-CABG definition was 38 and 31%, respectively, when ticagrelor/clopidogrel was discontinued, 24 h before surgery. Within the ticagrelor group, there was no significant difference between discontinuation 72 –120 or 120 h before surgery (OR 0.93; 95% CI 0.53–1.64; P = 0.8).

Secondly, for surgery with a high bleeding risk as cardiac surgery that requires the discontinuation of dual antiplatelet therapy, the strategy regarding the peri-procedural management of APA must be the result of a multidisciplinary consensus involving cardiologists or vascular specialists, anesthesiologists, and surgeons or interventional physicians. All non-urgent surgery should be delayed until the anti-P2Y12 drug can be safely withdrawn. In this case, if we need an emergency cardiac surgery for patients, ticagrelor should be stopped at least 24-96 hours before [7].

Finally, the antplatelet of choice between clopidogrel and ticagrelor after stabilisation of a major bleeding episode in patients who are at risk of acute stent thrombosis is undefined. The decision for clopidogrel was made on the basis of our greater clinical experience with this drug and the fact that the patient had bled whilst on ticagrelor. To
compare hemorrhagic events between clopidogrel and ticagrelor in the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor significantly increased spontaneous bleeds, major bleeds, major plus minor bleeds, and major plus minor plus minimal bleeds. Moreover, a study found that ticagrelor increased CABG-related bleeding versus clopidogrel in those patients who did not wait until day 5 after stopping treatment to have CABG. Additionally, compared to clopidogrel, ticagrelor increased the risk of hematuria (RR 1.91; 95% CI 0.95–3.83), intracranial hemorrhage or subdural or other hematoma (RR 1.87; 95% CI 1.02–3.42), subcutaneous hemorrhage, ecchymosis, hematoma (RR 1.63; 95% CI 0.84–3.17), epistaxis (RR 1.49; 95% CI 0.67–3.32), retroperi toneal hematoma or hemorrhage (RR 1.49; 95% CI 0.53–4.19), gastrointestinal/anal bleed (RR 1.23; 95% CI 0.93–1.64) and bleed/hematoma (RR 1.21; 95% CI 1.02–1.43) [8].

In conclusion, it was specifically designed to address the limitations of the available antiplatelet agents while maintaining comparable or better antiplatelet effects. Nonetheless, ticagrelor is a drug that has the potential to change the standard of care of patients with acute coronary syndromes.

References


